179 related articles for article (PubMed ID: 12634749)
1. Danish biotech centre faces axe.
Abbott A
Nature; 2003 Mar; 422(6928):105. PubMed ID: 12634749
[No Abstract] [Full Text] [Related]
2. Science philanthropy. Gates grows UW's genome program.
Service RF
Science; 2003 May; 300(5620):723. PubMed ID: 12730571
[No Abstract] [Full Text] [Related]
3. Universities could gain from backing biotech.
Kamb A
Nature; 2003 Mar; 422(6928):113. PubMed ID: 12634753
[No Abstract] [Full Text] [Related]
4. Sustainability and the balancing of the health care and innovation agendas: the commercialization of genetic research.
Caulfield T
Sask Law Rev; 2003; 66(2):629-45. PubMed ID: 15212021
[No Abstract] [Full Text] [Related]
5. Blurred vision.
Smaglik P
Nature; 2002 Dec; 420(6916 Suppl):A19, A21, A23. PubMed ID: 12501122
[No Abstract] [Full Text] [Related]
6. Australian states compete for biotech primacy.
Norrie C
Nat Biotechnol; 2002 Aug; 20(8):760. PubMed ID: 12147988
[No Abstract] [Full Text] [Related]
7. Share slump brings biotech firms to government's door.
Check E
Nature; 2003 Jun; 423(6943):908. PubMed ID: 12827159
[No Abstract] [Full Text] [Related]
8. Don't feed the trolls.
Nature; 2014 Jun; 510(7503):7. PubMed ID: 24910865
[No Abstract] [Full Text] [Related]
9. The evidence dilemma and cultural change.
Holtzman NA
Health Aff (Millwood); 2009; 28(3):925-6; author reply 926-7. PubMed ID: 19414911
[No Abstract] [Full Text] [Related]
10. Berkeley dispute festers over biotech deal.
Dalton R
Nature; 1999 May; 399(6731):5. PubMed ID: 10331373
[No Abstract] [Full Text] [Related]
11. Boston: a magnetic hub.
Smaglik P
Nature; 2002 May; 417(6886):4-5. PubMed ID: 12015552
[No Abstract] [Full Text] [Related]
12. Upending the zeitgeist.
Nature; 2006 Jun; 441(7093):572-3. PubMed ID: 16738631
[No Abstract] [Full Text] [Related]
13. No mistake in Berkeley's biotechnology deal.
Hultin PG
Nature; 2004 Oct; 431(7009):627. PubMed ID: 15470401
[No Abstract] [Full Text] [Related]
14. Biotech project in turmoil as Michigan balances books.
Knight J
Nature; 2003 Mar; 422(6928):102. PubMed ID: 12634742
[No Abstract] [Full Text] [Related]
15. Japanese rules hinder commercialization of publicly funded projects.
Triendl R
Nat Biotechnol; 2002 Apr; 20(4):325. PubMed ID: 11923824
[No Abstract] [Full Text] [Related]
16. Canadian lab loses Amgen backing.
Knight J
Nature; 2002 May; 417(6884):4. PubMed ID: 11986629
[No Abstract] [Full Text] [Related]
17. India's budget keeps dream of genomics hub alive.
Padma TV
Nature; 2016 Mar; 531(7592):16-7. PubMed ID: 26935674
[No Abstract] [Full Text] [Related]
18. Confusion over cash for Indian biotech centre..
Chauhan VS
Nature; 2000 Mar; 404(6776):329. PubMed ID: 10746698
[No Abstract] [Full Text] [Related]
19. Maximizing state and federal spending while minimizing conflicts.
Billingsley ML; Washko M
Nat Biotechnol; 2006 Dec; 24(12):1473-4. PubMed ID: 17160036
[No Abstract] [Full Text] [Related]
20. Funding crisis for Indian biotech centre.
Jayaraman KS
Nature; 2000 Feb; 403(6771):694. PubMed ID: 10733382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
